Search

Your search keyword '"Kenneth H. Shain"' showing total 206 results

Search Constraints

Start Over You searched for: Author "Kenneth H. Shain" Remove constraint Author: "Kenneth H. Shain"
206 results on '"Kenneth H. Shain"'

Search Results

1. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

2. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

3. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease

4. Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

5. #1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma

6. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

8. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

9. Replicative Instability Drives Cancer Progression

10. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas

11. A pharmacodynamic model of clinical synergy in multiple myeloma

12. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

13. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

14. Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

15. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

16. Data from Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma–Induced Osteolysis and Reduces Overall Survival

18. Supplemental Figures and Tables from An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma

19. Data from An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma

20. Supplemental Figure 6 from An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma

21. Supplementary Figures 1-14 from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

22. Supplementary Methods and Materials from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

23. Data from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

24. Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

25. Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

26. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

27. Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

28. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous proteasome inhibitor resistant disease

29. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma

30. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation

31. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma

32. Abstract 452: Novel autophagy inhibitory strategies to overcome chemotherapy resistance in multiple myeloma

33. Abstract 4313: A novel gene regulatory network model identifies master regulators in cancer

34. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma–Induced Osteolysis and Reduces Overall Survival

35. Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

40. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

41. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

42. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma

43. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

44. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

45. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies

46. Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myeloma

47. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

48. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms

49. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas

50. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Catalog

Books, media, physical & digital resources